Breaking News Headlines Today | Ground News

Cyber Week Sale - Get 40% off Vantage

Express Pharma image

News from Express Pharma

Ground News rates Express Pharma’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Express Pharma’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Express Pharma

Where is Express Pharma located?Express Pharma's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Express Pharma News

Sun Pharma Receives US FDA Label Update Approval for UNLOXCYT

Richmond, Kentucky · Richmond

Sun Pharma Receives US FDA Label Update Approval for UNLOXCYT

75% Center coverage: 32 sources

Sun Pharmaceutical announced the US Food and Drug Administration (FDA) approved an updated label for UNLOXCYT (cosibelimab-ipdl) for the treatment of adults with metastatic CSCC or locally advanced CSCC who are not candidates for curative surgery or curative radiation. The updated label now incorporates long-term follow-up data from the pivotal CK-301-101 trial, a multicenter, multicohort, open-label study of 109 patients (31 with laCSCC; 78…See the Story

Lupin Gains USFDA Approval for New Cancer Biosimilar

Cancer · United States

Lupin Gains USFDA Approval for New Cancer Biosimilar

67% Right coverage: 3 sources

Lupin secures USFDA approval for Armlupeg, a biosimilar indicated for treating neutropenia in cancer patients. The drug, produced at Lupin’s Pune facility, offers a cost-effective alternative to Neulasta. Lupin aims to expand its biosimilar portfolio, enhancing healthcare accessibility in the US market.See the Story

SAI Parenteral’s Ltd. Expands Global Reach with INR 125 Crore Acquisition of Australia’s Noumed Pharmaceuticals - Business News Week

Pharma · South Australia

SAI Parenteral’s Ltd. Expands Global Reach with INR 125 Crore Acquisition of Australia’s Noumed Pharmaceuticals - Business News Week

Hyderabad, Dec 01: SAI Parenteral’s Limited (SPL), a diversified pharmaceutical formulation company, today announced the acquisition of a 74.6% controlling stake in Noumed Pharmaceuticals Pty Ltd, an Adelaide-based pharmaceutical company, for an aggregate sum of INR 125 crore. SAI Parenterals has also filed its IPO DRHP with SEBI in September 30, 2025 – the offer, with […] The post SAI Parenteral’s Ltd. Expands Global Reach with INR 125 Crore Ac…See the Story

Breaking News Topics Related to Express Pharma